Latest From NASA
Our monthly update on technology transfer deals--licensing agreements between companies and universities or other research institutions--in the fields of life sciences, including in vitro diagnostics, pharmaceuticals, research/analytical equipment & supplies, and medical devices.
A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
The rates of reoperation after breast conservation therapy vary between 25 and 49%, due to the presence of tumor cells remaining in the surrounding tissue after the tumor is removed. NovaScan hopes to reduce the need for these reoperations. Its FastPath residual cancer probe is designed to identify normal, benign and malignant tissue types remaining inside the surgical cavity and in excised tissue in real time during surgery.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.